5 Results for "

TIGIT/CD155

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "TIGIT/CD155" in MCE Product Catalog:

Cat. No.: HY-P990155
Anti-Mouse TIGIT Antibody (1G9) is a mouse-derived agonistic TIGIT IgG1 κ type antibody. Anti-Mouse TIGIT Antibody (1G9) blocks CD155 binding to TIGIT. Anti-Mouse TIGIT Antibody (1G9) shows potent anti-infection and anti-immune effects in septic and experimental autoimmune encephalomyelitis .
loading...
    loading...
Cat. No.: HY-P99858
CAS No.: 2368219-35-4
Synonyms: AB154

Research Areas:  

Cancer

Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
loading...
    loading...
Cat. No.: HY-P99949
CAS No.: 2044984-83-8
Synonyms: OMP-313M32

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .
loading...
    loading...
Cat. No.: HY-P990031
CAS No.: 2649362-29-6
Synonyms: M-6223
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
loading...
    loading...
Cat. No.: HY-P991620

Research Areas:  

Cancer

JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .
loading...
    loading...